Stock PILL CANNTAB THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Canntab Therapeutics Limited

Equities

PILL

CA1377991023

Delayed Canadian Securities Exchange
Other stock markets
 02:07:30 2023-10-04 pm EDT 		5-day change 1st Jan Change
0.005 CAD -.--% Intraday chart for Canntab Therapeutics Limited -.--% -.--%
Apr. 15 Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding CI
2023 Canntab Therapeutics Limited Provide an Update on Product Delivery CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding
CI
Canadian Investment Regulatory Organization Trading Halt - PILL
AQ
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order
NE
Canntab Therapeutics Limited Provide an Update on Product Delivery
CI
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO
AQ
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023
CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022
CI
IIROC Trade Resumption - PILL
AQ
IIROC Trading Halt - PILL
AQ
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022
CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt
CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022
CI
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO
AQ
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market
MT
CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET
AQ
Canntab Therapeutics Limited Announces Chief Executive Office Changes
CI
CANNTAB ANNOUNCES CHANGE OF AUDITOR
AQ
Canntab Therapeutics : 2022Feb28 Q3 Interim MD&A
PU
Canntab Therapeutics : 2022Feb28 q3 Interim FS
PU
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PILL Stock
  4. News Canntab Therapeutics Limited